Clinical Trials Sponsored by EMDR Foundation

Total 16025 results

EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M1774 in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada, Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Met Non Small Cell Cancer Registry (MOMENT)

Cancer

United States, Israel, Spain, Finland, France, Belgium, Netherlands, United Kingdom, Canada, Italy, Germany, Sweden, Austria, Czechia, Portugal
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Cholangiocarcinoma | Biliary Tract Cancer | Gallbladder Cancer

Korea, Republic of, United States, Taiwan, Italy, France, China, Japan, Spain, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)

Advanced Solid Tumors

Canada, United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone

Multiple Myeloma

United States, France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE)

Coronavirus Disease 2019

United States, Brazil, Philippines
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Evobrutinib in Participants With RMS

Relapsing-remitting Multiple Sclerosis

United States, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First-in-Human Study of MS201408-0005A as Single Agent and in Combinations

Metastatic or Locally Advanced Unresectable Solid Tumors

United States
Merck KGaA, Darmstadt, Germany
EMD Serono, a division of EMD Inc., Canada

Completed

A Canadian, Multi-centre, Observational Registry to Study Adherence and Long Term Outcomes of Therapy in Pediatric Subjects Using SAIZEN® Via Easypod™ Auto-injector for Growth Hormone Treatment (ECOS CAN)

Growth Disorders

Canada
University of Washington
EMD Serono

Active, not recruiting

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)

Stage III Merkel Cell Carcinoma AJCC v8 | Stage IIIB Merkel Cell Carcinoma AJCC v8 | Stage IIIA Merkel Cell Carcinoma AJCC v8

United States
Massachusetts General Hospital
EMD Serono

Completed

M6620 (VX-970) in Selected Solid Tumors

Osteosarcoma | Solid Tumor | Leiomyosarcoma

United States
NYU Langone Health
EMD Serono

Completed

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Glioblastoma

United States
University of Utah
EMD Serono

Completed

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Renal Cell Carcinoma

United States
Ottawa Fertility Centre
EMD Serono

Completed

Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)

Infertility | Poor Ovarian Reserve

Canada
Fundacion Miguel Servet
Hospital Universitario Getafe; Matia Foundation

Unknown

Impact of a Multicomponent Exercise Program on Functional Capacity in Frail Aged Participants With Cognitive Decline

Cognitive Impairment | Frail Elderly Syndrome

Spain
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Urothelial Carcinoma

United States, Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

Head and Neck Cancer

Taiwan, United States, Korea, Republic of, Spain, Belgium, Israel
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Portugal, Romania, Spain, Switzerland, Netherlands, P... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors

Central Nervous System Tumors

Korea, Republic of, United States, Canada, Germany, France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, China, Spain, Japan, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Bintrafusp Alfa Program Rollover Study

Cancer | Lung Cancer

Korea, Republic of, Spain, Germany, Japan, Taiwan, China, Italy, United States, Belgium, Russian Federation, Turkey, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

Non-small Cell Lung Cancer

Korea, Republic of, Taiwan, United States, China, Hong Kong, France, Russian Federation, Netherlands, Japan, Spain, Italy, Belgium, Vietnam, Malaysia, Thailand, Germany, Singapore
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

Multiple Sclerosis (MS)

United States, Lebanon, Spain, Sweden, Poland, Italy, Estonia, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Korea, Republic of, Lithuania, Norway, Portugal, Romania, Russian Federation and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

First in Human Study of M1069 in Advanced Solid Tumors

Metastatic or Locally Advanced Unresectable Solid Tumors

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M1231 in Participants With Solid Tumors

Esophageal Cancer | Non-Small Cell Lung Cancer | Metastatic Solid Tumors

United States, Canada
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib Hepatic Impairment Trial

Hepatic Impairment

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Advanced Solid Tumors

United States, Germany, Norway, Netherlands, Belgium, Denmark, Sweden, Switzerland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Phase II Study of M2951 in SLE

Systemic Lupus Erythematosus

Philippines, United States, Korea, Republic of, Malaysia, Taiwan, Germany, Italy, Poland, Mexico, Bulgaria, Peru, Argentina, Chile, Colombia, Japan, Mauritius, Romania, Russian Federation, South Africa
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

Ovarian Cancer

Belgium, United States, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Ukraine, United States, Czechia, Poland, Argentina, Mexico, South Africa, Chile, Bulgaria, Colombia, Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

M6620 First in Human Study

Advanced Solid Tumor

United States, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Relapsing-Remitting Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

MSC2364447C Phase 1b in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Bulgaria
Calmy Alexandra
University Hospital, Geneva; Swiss National Science Foundation; Swiss Heart Foundation and other collaborators

Terminated

ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART (NILACH)

Atherosclerosis | HIV

Switzerland
Centre Hospitalier Chretien
EMD Serono

Withdrawn

Study of Optimal Posology of Gonadotrophins in Patients With Insufficient Ovarian Response Due to Age

Infertility

Belgium
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Study of M5049 in DM and PM Participants (NEPTUNIA)

Dermatomyositis | Polymyositis

United States, Italy, Spain, Greece, Czechia, United Kingdom, Poland
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

Multiple Sclerosis

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab Program Rollover Study

Solid Tumors

Korea, Republic of, United States, Spain, United Kingdom, Russian Federation, Argentina, Australia, Italy, Japan, Belgium, Brazil, Czechia, France, Germany, Hungary, Romania, Turkey, Bulgaria, Mexico, Poland, Thailand, Ukraine
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)

Systemic Lupus Erythematosus

Korea, Republic of, United States, Taiwan, China, Poland, Brazil, Argentina, Chile, Philippines, Australia, Colombia, Bulgaria, Mexico, Serbia, Greece, Spain, Israel, Japan, Mauritius, Moldova, Republic of, Romania, South Africa
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

Solid Tumors

Korea, Republic of, United States, Belgium, Spain, Italy, Taiwan, Canada, Australia, United Kingdom, Germany, France, Japan
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Spain, Czechia, Bulgaria, Serbia, Russian Federation, Ukraine, Poland, Slovakia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more

Clinical Trials Sponsored by EMDR Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations